Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical SUPN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Outside Day | Range Expansion | 2.38% | |
| Up 3 Days in a Row | Strength | 2.38% | |
| Strong but Oversold | Other | 3.77% | |
| Oversold Stochastic | Weakness | 3.77% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 3.95% | |
| Lower Bollinger Band Touch | Weakness | 3.95% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 20 DMA Resistance | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 2% | 2 days ago |
| Up 1% | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/03/2021
Supernus Pharmaceuticals, Inc. Description
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Research Clinical Trial Chloride Neurology Epilepsy Depression Attention Deficit Attention Deficit Hyperactivity Disorder Clinical Trial Product Central Nervous System Disease Hyperactivity Disorder Central Nervous System Diseases Investigational New Drug Treatment Of Central Nervous System Diseases Treatment Of Depression Treatment Of Epilepsy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.31 |
| 52 Week Low | 17.2 |
| Average Volume | 528,631 |
| 200-Day Moving Average | 24.99 |
| 50-Day Moving Average | 28.65 |
| 20-Day Moving Average | 30.58 |
| 10-Day Moving Average | 29.88 |
| Average True Range | 1.09 |
| ADX | 18.75 |
| +DI | 19.19 |
| -DI | 19.69 |
| Chandelier Exit (Long, 3 ATRs ) | 29.05 |
| Chandelier Exit (Short, 3 ATRs ) | 31.88 |
| Upper Bollinger Band | 32.36 |
| Lower Bollinger Band | 28.80 |
| Percent B (%b) | 0.49 |
| BandWidth | 11.63 |
| MACD Line | 0.14 |
| MACD Signal Line | 0.35 |
| MACD Histogram | -0.2074 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 32.30 | ||||
| Resistance 3 (R3) | 32.13 | 31.37 | 32.00 | ||
| Resistance 2 (R2) | 31.37 | 30.93 | 31.46 | 31.90 | |
| Resistance 1 (R1) | 30.96 | 30.65 | 31.17 | 31.13 | 31.81 |
| Pivot Point | 30.20 | 30.20 | 30.31 | 30.29 | 30.20 |
| Support 1 (S1) | 29.79 | 29.76 | 30.00 | 29.96 | 29.27 |
| Support 2 (S2) | 29.03 | 29.48 | 29.12 | 29.18 | |
| Support 3 (S3) | 28.62 | 29.03 | 29.08 | ||
| Support 4 (S4) | 28.79 |
